Page 339 - Binder2

And because plants don’t harbor mammalian viruses, the
contamination risk profile is different—and arguably
lower. There’s no risk of adventitious viral agents from
CHO cells or animal-derived reagents. Microbial
monitoring is still required, but the sterility requirements
are based on oral, not injectable, standards—further
reducing cost and complexity.

Decentralized Doesn’t Mean Disorganized

Critics may argue that decentralization introduces
variability. But with Zea’s AI-powered process control and
standard operating procedures, consistency can be
achieved across sites—without industrial-scale
overhead.

Each site doesn’t need to be a clone of a $500M
biomanufacturing plant.
It needs to follow a validated, monitored process—with
digital oversight and rapid feedback loops.

This is distributed precision—not disorganized
production.

The Strategic Threat

For legacy manufacturers, this model is deeply unsettling.
It undermines one of their most powerful tools: the ability
to control supply, pricing, and access by virtue of
infrastructure scale.

337